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Beyond the Harvard Mouse: Current
Patent Practice and the Necessity of Clear
Guidelines in Biotechnology Patent Law
CARRIE F. WALTER'
INTRODUCTION
Biotechnology is a field that is capable of modem-day miracles. Yet it is also
a field that evokes a certain "Frankenstein Factor,"' because those who fail to
understand the benefits of biotechnology fear that tampering with natural biology
will result in creatures meant only for science-fiction novels. Research in
biotechnology has been met with many well-grounded moral and philosophical
disagreements, and it is true that biotechnological advances have progressed at
a furious pace despite the uncertain nature of the science.2 Accompanying the
debates about biotechnology itself has been a debate about whether
biotechnological advances such as transgenic3 animals and human gene
sequences should be patentable.
Patents stimulate the growth of industry, and the industry of biotechnology
welcomes any patent protection it receives. Due to the controversial nature of
patenting "life," or products intimately associated with life, it is necessary to
pursue patent protection with solid grounding in patent law that is adequately
suited to biological advances. The idea of an animal patent exploded onto the
scene in 1988 when the Patent and Trademark Office ("PTO") issued its first
animal patent to the transgenic mouse known as the "Harvard Mouse."4 Heated
debates ensued, but no clear policy was ever articulated regarding animal patents.
* J.D. Candidate, 1998, Indiana University School of Law-Bloomington; A.B., 1995,
Duke University. Thanks to Professor Fred Cate for his helpful comments on the first draft of
this Note. Special thanks to my parents, Don and Cidney Walter, my brothers, Rich and John
Walter, and my fianc6, Matt Cotter, for their constant encouragement, support, and
unconditional love.
I. Dan L. Burk, Patenting Transgenic Human Embryos: A Nonuse Cost Perspective, 30
Hous. L. REv. 1597, 1643 (1993).
2. See Revitalizing New Product Development from Clinical Trials Through FDA Review:
Hearing of the Senate Comm. on Labor and Human Resources on S. 1477, 104th Cong. 106
(1996) [hereinafter Revitalizing New Product Development] (statement of David A. Kessler,
Commissioner, Food and Drug Administration, Department of Health and Human Services).
3. Transgenic animals are those which have been permanently altered by introducing
foreign deoxyribonucleic acid ("DNA") into a fertilized mammalian egg. See BRUCE ALBERTS
ET AL., MOLECULAR BIOLOGY OF THE CELL 267-68 (2d ed. 1989).
4. See U.S. Pat. No. 4,736,866 (Apr. 12, 1988). The mouse was developed by Philip Leder
(of Harvard University) and Timothy Stewart (of Genentech). The Harvard Mouse is a
genetically engineered mouse which is highly prone to breast cancer. See Michael B. Landau,
Multicellular Vertebrate Mammals as "Patentable Subject Matter" Under 35 U. S.C. § 101:
Promotion of Science and the Useful Arts or an Open Invitationfor Abuse?, 97 DICK. L. REV.
203,213-14 (1993).
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Rather, the PTO accepted transgenic animals as patentable subject matter,
essentially, by default.'
Now applications have been filed and patents have been granted for human
gene sequences, 6 and the existing law regarding animal patents does not provide
a solid foundation for dealing with this new innovation. Additionally, Canada
recently rejected the patent application for the very Harvard Mouse that created
the controversy over animal patenting in the United States,7 again suggesting that
the debate about animal patenting is, indeed, unresolved and anything but clear-
cut.
This Note focuses on the legal and social concerns that surround the patenting
of transgenic animals and human gene sequences, and suggests means of dealing
with these problems while still allowing such biological advances to be
patentable. Part I of this Note gives an explanation and synopsis of
biotechnology and its uses. Part II describes the current state of patent law and
the suitability of transgenic animals and human gene sequences to the current
law. Part III considers the social and ethical concerns involved in biotechnology
and its patenting. Finally, Part IV discusses the limits of patents on
biotechnology and weighs the costs and benefits of allowing patents on
biotechnology. The economic and social benefits will eventually far outweigh the
costs involved with patenting transgenic animals and human gene sequences.
Eventually, it will become apparent that the root of the debate about patents for
biotechnology has less to do with patent law, and more to do with fundamental
concerns about the science itself. Specialized commissions such as the National
Bioethics Advisory Commission ("NBAC" or "Commission") are better suited
to deal with the moral and ethical problems presented by experimentation with
transgenic animals and human gene sequences. The role of the PTO has been,
and should remain, to decide novelty and not morality! Sufficiently novel
discoveries in biotechnology should receive patent protection as discoveries in
all other fields do.
5. See Mark 0. Hatfield, From Microbe to Man, I ANIMAL L. 5 (1995).
6. See, e.g., U.S. Pat. No. 5,362,623 (Nov. 8, 1994) (granting patent for gene that,
apparently, causes cancer); U.S. Pat. No. 5,220,013 (June 15, 1993) (granting patent
application for a DNA sequence useful in the detection of Alzheimer's disease); U.S. Pat. No.
5,169,941 (Dec. 8, 1992) (granting patent application for DNA sequence useful in diagnosing
multiple sclerosis).
7. See Appeal Filed Against Rejection of "Harvard Mouse" Application, BNA Pat.
Trademark & Copyright L. Daily (Mar. 26, 1996), available in WESTLAW, 3/26/96 PTD d3.
The Commissioner of Patents in Canada was not ready to extend the definition of invention to
include nonhuman mammals primarily because of the inability to control reproduction. See id.
8. See With Science Blooming, "Tough" Patent Fight Looms for Transgenic Animals,
BIOTECH. NEWSWATCH, Mar. 1, 1993, available in 1993 WL 2450029 [hereinafter Science
Blooming].
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I. DNA: BACKGROUND, USES, AND TECHNIQUES
Scientists knew that a long chain-like molecule existed which encoded genetic
information as far back as the 1920s; 9 however, it took over thirty years to
identify DNA." Once discovered, however, the field of biotechnology exploded
in a very short time. James Watson and Francis Crick discovered the DNA
molecule in 1952,11 and from there spawned a fascinating new field of
experimentation and research which resulted in the blindingly fast-paced world
of biotechnology. Better food, healthier livestock, less expensive
pharmaceuticals, and more accurate laboratory testing techniques are only a few
of the examples of the ways in which biotechnology can improve our world. 2 To
better understand, a little background on the history and techniques of the field
is necessary.
A. A Brief History and Description of DNA
In 1952, James Watson and Francis Crick discovered that the DNA molecule
was shaped like a long, twisted ladder. They described this shape as a double
helix.'3 The "sides" of the double helix are composed of deoxyribose (a sugar),
and the "rungs" of the double helix are composed of bases, which pair together
to bring the two sides together.' 4 Four bases are found in DNA: adenine (A),
cytosine (C), guanine (G), and thymine (T).'5 The bases combine with the
deoxyribose to form "nucleotides."' 6 The double helix of DNA is formed by
joining two strands of nucleotides. The bases are always found as
"complementary base pairs": adenine always pairs with thymine on opposite
strands, and guanine always pairs with cytosine on opposite strands.' Both
9. See John Richards, International Aspects of Patent Protection for Biotechnology, 4
FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 433, 434-35 (1993).
10. DNA is the building block of genetic material. It was not until the 1950s that it was
generally accepted that DNA was the carrier of genetic information; however, today DNA and
its role in genetic coding are absolutely fundamental to biological thought See ALBERTS ET AL.,
supra note 3, at 95.
11. See DAVID SUZUKI & PETER KNUDTSON, GENETHICs 24 (rev. & updated ed. 1990).
12. See generally Diana A. Mark, All Animals Are Equal, but Some Are Better than Others:
Patenting Transgenic Animals, 7 J. CoNTEMP. HEALTH L. & POL'Y 245 (1991); Thomas Traian
Moga, Transgenic Animals as Intellectual Property (or The Patented Mouse That Roared), 76
J. PAT. [&TRADEMARK] OFF. SO'y 511 (1994); Michael E. Sellers, Patenting Nonnaturally
Occurring, Man-Made Life: A Practical Look at the Economic, Environmental, and Ethical
Challenges Facing "Animal Patents", 47 ARK. L. REV. 269 (1994); David Manspeizer, Note,
The Cheshire Cat, the March Hare, and the Harvard Mouse: Animal Patents Open Up a New,
Genetically-Engineered Wonderland, 43 RUTGERS L. REV. 417 (1991).
13. See SUZUKI & KNUDTSON, supra note 11, at 24.
14. See ALBERTS ET AL., supra note 3, at 95.
15. See id.
16. A nucleotide is the combination of a sugar and a base. See Richards, supra note 9, at
435.
17. See ALBERTS ET AL., supra note 3, at 96.
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strands of the double helix contain the same information because their structures
are exactly complementary to each other. Each side of the DNA, therefore,
creates a "template" for making the other side." This structure suggests that
information transfer is accomplished by a process where the two strands of the
DNA molecule separate and serve as a template for creating the partner strand. 9
The base pairs form a sort of alphabet that spells out the codes for amino acids.
Every sequence of three base pairs signifies a codon. Each codon codes for an
amino acid. Different combinations of amino acids, then, "spell" out the codes
for different proteins.2" Through complicated processes known as transcription
and translation, this series of codons is "read" by the DNA in order to produce
the desired proteins.2' Changing any base pair disrupts the sequence, thereby
changing the code, and has the potential to create completely different proteins
from those originally encoded on the original DNA. Once this initial form and
function of DNA was discovered, genetics technology moved incredibly fast.
By 1956, twenty-three chromosomes 2 had been discovered. By 1966, DNA's
complete genetic code had been deciphered. And by 1972, the first recombinant
DNA molecule had been created in a laboratory.
B. Recombinant DNA Technology
Recombinant DNA ("rDNA") technology creates new DNA sequences by
joining pieces of DNA from different organisms together. 24 Bacterial enzymes
known as nucleases cut specific DNA sequences, then other enzymes known as
ligases allow reconnection into severed DNA strands.25 This splicing and
recombination of the DNA sequences results in totally new DNA in the host
organism or cell. The host cell or organism may then express the foreign DNA
by creating the desired proteins that would not have been produced had the DNA
not been altered. 26 This sort of technology allows the genes responsible for the
production of such proteins as insulin or human growth hormone to be
introduced into bacteria or other hosts so that the new host will produce the
18. See id.
19. See id.
20. See id. at 102.
21. See Rochelle K. Seide & Frank A. Smith, Intellectual Property Protection and
Biotechnology, 67 N.Y. ST. B.J., May/June 1995, at 53.
22. A chromosome is a "condensed rod made up of a linear thread of DNA interwoven with
protein that is the gene-bearing structure of eukaryotic cells." SUZUKI & KNJDTSON, supra note
11, at 340.
23. See id. at 26.
24. See id. at 348.
25. See Burk, supra note 1, at 1606-07. This technique may be used to cut and paste DNA
sequences within an organism, or even from one species to another. Vectors are then used to
introduce the new DNA into a host cell or species. When dealing with bacterial subjects,
plasmids'are used as vectors. When dealing with more complicated organisms, viruses are used
as vectors. See id.
26. See Seide & Smith, supra note 21, at 54.
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desired product.27 It is rDNA technology which first created the need for
intellectual-property protections in the field of biotechnology."
The Harvard Mouse, a genetically engineered mouse designed for cancer
research, was the subject of the first animal patent in the United States.29 This
mouse was created through a genetic-engineering technique known as
microinjection.3 0 First, purified copies of genes are injected directly into a
fertilized animal egg. The egg is then surgically implanted into the mother so that
she may bring it to term. Although very few of the injections result in the live
birth of a transgenic animal, successful injections result in offspring which
exhibit traits attributable to the inserted genes.3' To create the Harvard Mouse,
a laboratory mouse was injected with a gene known to cause cancer. The
resulting transgenic mice were extremely prone to breast cancer. 2
The Harvard Mouse serves as a valuable research tool. Because these mice are
so sensitive to carcinogens, they act as detectors so that scientists can monitor
both the sources of the disease and the causes. Scientists insert human genes into
the mice which mutate when exposed to carcinogens. Then, when testing a
carcinogenic substance, the gene mutates indicating the carcinogenic nature of
the substance. With the mice more prone to the cancers, a known time frame for
developing cancer is present. If the mouse develops cancer significantly sooner
than the known time frame with the introduction of the carcinogen, the
carcinogen may be implicated in the cause of human breast cancer?3 This is a
good example of an invaluable medical-research tool; however, biotechnology
has useful applications in many fields.34
C. The Uses of Transgenic Animals and Human Gene
Sequences
Transgenic animals and human gene sequences have enormous commercial
value in agriculture, biomedical research, medicine, and the pharmaceutical
industry among other fields.3" The social impact of these forms of biotechnology
is nearly limitless. In addition to providing accurate and cost-effective models for
the study of human disease, transgenic animals are capable of improving food
27. See Richards, supra note 9, at 436.
28. See Seide & Smith, supra note 21, at 53. The need arose because scientists could now
create new and different organisms through the use of rDNA.
29. See Landau, supra note 4, at 213.
30. Microinjection is a technique which requires injection of purified genes into a fertilized
animal egg. The animal's own enzymes, then, take care of splicing the DNA in order to
incorporate the novel DNA into that of the organism. As the cell develops into a full-grown
organism, the introduced DNA will have made itself part of the genetic code of each cell within
the organism. See Malcolm Gladwell, Building a Better Mouse to Minimize Lab Guesswork,
WASH. POST, Oct. 30, 1989, at A3.
31. See Sellers, supra note 12, at 272.
32. See Landau, supra note 4, at 214.
33. See Gladwell, supra note 30, at A3.
34. See Terri A. Jones, Note, Patenting Transgenic Animals: When the Cat's Away, the
Mice Will Play, 17 VT. L. REv. 875, 877 (1993).
35. See id. at 880-81.
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sources and disease resistance in animals. Additionally, it is possible, through
transgenic technology, to engineer animals to produce pharmaceutical products
in their milk or organs capable of being transplanted into humans. 36 It is true that
the initial projections about the pace of biotechnological advancement were too
optimistic; however, even though the innovations are proceeding more slowly
than originally thought, many new and important advancements have been
made.37
1. Health Care and Medical Research
Because transgenic animals make researching causes and possible treatments
of disease easier, they have been called a "gold mine for researchers."38
Scientists use mice, such as the Harvard Mouse, as living laboratories that
remove significant amounts of the guesswork from toxicological studies.39
Scientists remove this guesswork by "color-coding" the genes they insert into a
mouse. The color shows up when a mutation occurs, thus signaling the harmful
nature of a chemical.4" Transgenic animals allow a quick check for a color change
in germ cells to signal mutation, whereas currently thousands of laboratory
subjects are required for similar testing." These mammalian subjects'are much
more valuable for testing than were the previous bacterial subjects. An animal is
more likely than a single-celled bacterium to exhibit the characteristics that a
multicellular human would when exposed to certain chemicals.42 Additionally,
some chemicals cause mutations that are not apparent until future generations.
Transgenic animals allow study on the first-generation animal as well as its
subsequent generations, thereby allowing researchers to observe the effects of
the genetic mutations in the transgenic animal's offspring.43 The results of
36. See Moga, supra note 12, at 527.
37. See Burk, supra note 1, at 1606-15.
38. Maria Cone, The Mouse Wars Turn Furious, L.A. TIMES, May 9, 1993, at Al.
39. See Manspeizer, supra note 12, at 426. Toxicological studies are those that distinguish
between harmless and harmful chemicals. See Gladwell, supra note 30, at A3.
40. Scientists are able to insert genes into mice with characteristics that could turn a cell
blue or make it glow. Scientists engineer the gene so that it will only exhibit this color
characteristic if the chemical being tested will mutate the cell back to its original form. See
Gladwell, supra note 30, at A3.
41. See Manspeizer, supra note 12, at 426-27.
42. See id. at 427. Even more guesswork is removed in cancer research because the
laboratory subjects do not have to be exposed to huge doses of carcinogen to obtain results.
Rather than using huge exposure to carcinogens, researchers may expose the transgenic mice
to amounts of carcinogen more similar to those doses humans may be experiencing. See
Advances in Genetics Research and Technologies: Challenges for Public Policy: Hearings
Before the Senate Comm. on Labor and Human Resources, 104th Cong. 47-48 (1996)
[hereinafter Advances in Genetics Research] (statement of Francis Collins, M.D., Director,
National Center for Human Genome Research).
43. See Gladwell, supra note 30, at A3.
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studies with transgenic animals are quicker, less expensive, and more realistic
than previous methods."
Transgenic animals improve the quality of disease study in many cases; but in
other cases, transgenic animals are the only way to study disease. Some
substances which are harmful to humans do not appear as harmful in animal
subjects.4" By inserting human genes into the animals, serious human ailments
may be studied without the use of any human subjects.46 Currently transgenic-
animal disease models exist for AIDS,47 sickle cell anemia, Down's syndrome,
hepatitis B, Alzheimer's disease, high cholesterol,48 and various cancers.4 9
Beyond simply creating disease models, scientists hope transgenic animals will
be the source of donor organs in the future."0
Researchers have already successfully transplanted human organ tissue into
mice,"' and researchers hope that the use of "near human" organs such as livers,
kidneys, or hearts of animals will be used in the future for those in need of
transplants.5 2 By developing transgenic animals that create human proteins,
scientists expect they will be able to create animal organs that the human body
will not reject after transplantation. 3
Finally, by developing transgenic animals as disease models, pharmaceutical
companies have a more economic and realistic way to test their products. By
creating the animals to be prone to certain ailments, pharmaceutical companies
may test the effectiveness of vaccines and drugs.54 The pharmaceutical industry
44. See Advances in Genetics Research, supra note 42, at 47-48. Because of the more
realistic nature of the testing performed on transgenic animals, researchers should be able to
gain a better understanding of the molecular and cellular levels of disease. This, in turn, should
improve the ability to study intervention and protection techniques in the environment to limit
human exposure. See id.
45. A frequently cited example of this is the extensive animal testing which took place with
thalidomide before it was administered to pregnant women. The harmful effects to human
fetuses was not apparent in the animal testing. See Manspeizer, supra note 12, at 425-26.
46. See Malcolm Gladwell, Mouse Patent May Bolster Research Efforts, WASH. POST, Apr.
13, 1988, at F1.
47. The Ohio Mouse is used for testing AIDS. See Genetically Engineered Mouse Mighty
Big with Ohio U. Creators, PLAIN DEALER (Cleveland), Jan. 13, 1993, at 2G [hereinafter
Genetically Engineered Mouse].
48. See Burk, supra note 1, at 1634 & n.283.
49. See Transgenic Animals: Production and Use as Experimental Models for Human
Diseases, LIFE SCI. & BIOTECH. UPDATE, Jan. 1, 1996, available in 1996 WL 2088895; see also
supra text accompanying notes 29-32.
50. See Moga, supra note 12, at 536.
51. See Anticancer Applies for Transplanted Animal Patent, BIOTECH PAT. NEws, Oct. 1,
1991, available in 1991 WL 2730943.
52. See Moga, supra note 12, at 536.
53. See Departments of Labor, Health and Human Servs., Educ., and Related Agencies
Appropriations for 1997: Hearings Before a Subcomm. of the House Comm. on
Appropriations, 104th Cong. 218 (1996) (statement of Claude Lenfant, M.D., Director,
National Heart, Lung, and Blood Institute).
54. See Elisabeth T. Jozwiak, Comment, Worms, Mice, Cows and Pigs: The Importance
ofAnimal Patents in Developing Countries, 14 NW. J. INT'L L. & BUs. 620, 623 (1994).
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does not just utilize transgenic animals for research. Transgenic animals will be
very helpful in the actual production of pharmaceuticals as well.
2. Pharmaceutical Industry
The pharmaceutical industry uses both transgenic animals and human gene
sequences in order to help aid people with such ailments as genetic disorders,
hormone deficiencies, and enzyme deficiencies."5 By altering the DNA of some
animals, it is possible to create animals who secrete beneficial proteins in their
milk. 6 For example, a transgenic goat was created which produces in its milk a
drug used in the treatment of cystic fibrosis." A transgenic sheep also exists
which is able to produce up to five ounces a day of a protein used to treat
emphysema."9 Insulin, human growth hormone, and drugs for the treatment of
heart attack and stroke victims are all possible candidates for production in the
milk of transgenic animals.5 9
Animals have been used as "factories" for producing such proteins as human
growth hormone and insulin for a long time; however, the animals (usually pigs
and sheep) were previously sacrificed in order to obtain the protein. With
transgenic technology, it will no longer be necessary to slaughter the animals in
order to produce the proteins necessary for various pharmaceuticals.
Additionally, mass production of the proteins will be much easier and far more
cost effective.6 ' Because transgenic animals produce therapeutic proteins far
more economically than common methods do, some estimate the current cost to
consumers of such proteins will be reduced by as much as 100 times."2 Finally,
the quality of the drugs produced with transgenic animals and gene sequences
may be much higher than drugs produced synthetically 3 People expect similar
rewards for the use of transgenic animals in agriculture.
55. See Mark, supra note 12, at 251.
56. See Transgenic Animal-Based Protein Products Move Toward Clinical Trials, GENETIc
ENGINEERING NEWS, May 1, 1996, at 37, available in 1996 WL 9121156.
57. See Transgenic "Pharming" Drugs in Clinical Trials, 14 NAIiRE BIOTECH. 1205
(1996).
58. See Gene-Altered Animals Producing Disease-Fighting Human Protein, CHI. TRIB.,
Aug. 27, 1991, § 1, at 8. Five ounces is nearly a one-year supply for an emphysema patient. See
id.
59. See Mark, supra note 12, at 250.
60. See Moga, supra note 12; at 531.
61. For example, for one particular protein, a transgenic lamb was able to produce 18 times
the concentration than is usually found in human serum. If a herd is produced from this
transgenic animal, mass production of the protein would be quite possible and far less
expensive. See id. at 534-35.
62. See Manspeizer, supra note 12, at 427; see also Vicki Brower, PPL Floats IPO as
Companies Consider Transgenic Switch, 14 NATuRE BIOTECH. 692 (1996). Some of the
possible drugs for this method currently cost as much as $2200 per dose. See Gladwell, supra
note 46, at FI.
63. See Moga, supra note 12, at 532-34.
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3. Food and Agriculture
Creating transgenic animals for agriculture may lower costs to farmers by
creating animals that are better able to resist disease, have increased growth
performance, and have better reproductive traits. This benefit is two-fold as it
creates lower costs to the farmers and increases quality for the consumer.'
Researchers have been successful in creating larger and leaner fish, rabbits, and
sheep through transgenic technology.65 Additionally, the technology should
improve the production of cow milk.66
The concept of "engineering" animals to be better sources of food is not new.
Traditionally this has been accomplished through selective breeding. The
introduction of transgenic animals will improve the quality of animals within one
generation rather than through the long, multigenerational process of selective
breeding.67 Additionally, the problems traditionally associated with selective
breeding will be avoided.68 These transgenic animals will reduce costs for
farmers and provide many health benefits for consumers.69
II. PATENT LAW: PURPOSES, ORIGINS, AND THE
SUITABILITY OF BIOTECHNOLOGY TO PATENT PROTECTION
It is obvious that biotechnological advances have many uses that will benefit
public health and wellness. The research required to create these advances,
however, is very expensive to undertake. 0 Patent protection is one means by
which people with the genius to make technological advances are rewarded for
their willingness to undertake risky and expensive research, development, and
manufacture. The patents allow these people to receive benefits from their work,
but more importantly, the patents encourage further research and development.7'
If it is desirable to encourage further research in the field of biotechnology,
patent protection is both desirable and necessary.
64. See Sellers, supra note 12, at 271.
65. See Moga, supra note 12, at 530.
66. See id. at 527.
67. See Burk, supra note 1, at 1635.
68. See, e.g., Milk Implicated in Triggering Diabetes, Agence France-Presse, Feb. 27, 1997,
available in 1997 WL 2066974 (describing how selective breeding of cows in order to create
protein-rich milk has resulted in milk that may trigger diabetes in people); Auberon Waugh,
The Sad History of the Bulldog, SUNDAY TELEGRAPH (London), Mar. 9, 1997, Comment
Section, at 35, available in LEXIS, World Library, Telegr File (describing how selective
breeding of the bulldog has resulted in a head so large that caesarean section is necessary for
birth).
69. See David R. Pumell, International Implications of New Agricultural Biotechnology,
25 U. MEM. L. REV. 1189, 1191-92 (1995).
70. See David Beier & Robert H. Benson, Biotechnology Patent Protection Act, 68 DENY.
U. L.REv. 173, 190 (1991).
71. See id.
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A. The Origins of Patent Law in Biotechnology
U.S. patent law is grounded in Article I, Section 8, Clause 8 of the U.S.
Constitution.72 Title 35 of the United States Code codified the Patent Act of
1952. Rooted in each of these documents are the basic tenets of patent law:
novelty,73 utility,74 and nonobviousness.7 5 Title 35 U.S.C. § 101 states,
"[w]hoever invents or discovers any new and useful process, machine,
manufacture, or composition of matter, or any new and useful improvement
thereof, may obtain a patent therefor, subject to the conditions and requirements
72. Congress shall have the power "[t]o promote the Progress of Science and useful Arts,
by securing for limited Times to Authors and Inventors the exclusive Right to their respective
Writings and Discoveries." U.S. CONST. art. I, § 8, cl. 8.
73. See 35 U.S.C. § 102 (1994):
Conditions for patentability; novelty and loss of right to patent:
A person shall be entitled to a patent unless-
(a) the invention was known or used by others in this country, or patented or
described in a printed publication in this or a foreign country, before the invention
thereof by the applicant for patent, or
(b) the invention was patented or described in a printed publication in this or a
foreign country or in public use or on sale in this country, more than one year
prior to the date of the application for patent in the United States, or
(c) he has abandoned the invention, or
(d) the invention was first patented or caused to be patented, or was the subject
of an inventor's certificate, by the applicant or his legal representative or assigns
in a foreign country prior to the date of the application for patent in this country
on an application for patent or inventor's certificate filed more than twelve
months before the filing of the application in the United States, or
(e) the invention was described in a patent granted on an application for patent by
another filed in the United States before the invention thereof by the applicant for
patent, or on an international application by another who has fulfilled the
requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before
the invention thereof by the applicant for patent, or
(f) he did not himself invent the subject matter sought to be patented, or
(g) before the applicant's invention thereof the invention was made in this country
by another who had not abandoned, suppressed, or concealed it. In determining
priority of invention there shall be considered not only the respective dates of
conception and reduction to practice of the invention, but also the reasonable
diligence of one who was first to conceive and last to reduce to practice, from a
time prior to conception by the other.
74. See id. § 101.
75. See David G. Scalise & Daniel Nugent, International Intellectual Property Protections
for Living Matter: Biotechnology, Multinational Conventions and the Exception for
Agriculture, 27 CASE W. RES. J. INT'L L. 83, 89 (1995). Nonobviousness is discussed in 35
U.S.C. § 103:
A patent may not be obtained though the invention is not identically disclosed
or described as set forth in section 102 of this title, if the differences between the
subject matter sought to be patented and the prior art are such that the subject
matter as a whole would have been obvious at the time the invention was made
to a person having ordinary skill in the art to which said subject matter pertains.
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of this title."76 Much biotechnology falls beneath the "composition of matter"
portion of § 101. However, for many years, judicial doctrine limited
"composition of matter" to exclude products of nature from patentable subject
matter."
The products-of-nature doctrine prevents patents from being issued to
discoveries that do not require any invention.78 For many years, the products-of-
nature doctrine acted as a bar to patents pertaining to living matter. Once the
products-of-nature doctrine was purportedly overturned by the landmark case,
Diamondv. Chakrabarty,79 opponents used the Plant Patent Act of 193080 and the
Plant Variety Protection Act of 197081 to block animal patents. These opponents
stated that only those organisms which fall under the protection of one of those
acts should be afforded patent protection. 2
In 1980, the Supreme Court decided Diamond v. Chakrabarty8 3 which
addressed the patentability of a bacterium capable of breaking down crude oil.
Chakrabarty set the stage for animal patenting. Ananda M. Chakrabarty created
a genetically engineered bacterium capable of breaking down multiple
components of crude oil. Mr. Chakrabarty contended that, because of this
property, his bacterium possessed a trait not found in naturally occurring
bacteria, and, therefore, sought patent protection.84 The PTO denied Mr.
Chakrabarty's patent application on the grounds that the microorganisms are
products of nature and, as living things, per se nonpatentable.85 Mr. Chakrabarty
then appealed his claim all the way to the Supreme Court. The Court decided that
the language of 35 U.S.C. § 101 was sufficiently broad to encompass the living
microorganism, thus signaling the expansion of patent law to living matter. The
Court invited Congress to address the issue and exclude living organisms not
76.35 U.S.C. § 101.
77. See Scalise & Nugent, supra note 75, at 89-90.
78. See id at 90. For example, if you were to discover a new variety of plant, and then were
to realize it could be used for medicinal purposes in its natural form, you would not be able to
obtain a patent. Although it would be indisputable that your discovery is both new and useful,
there is no element of invention. See id.
79. 447 U.S. 303 (1980).
80. Pub. L. No. 71-245, 46 Stat. 376 (current version at 35 U.S.C. §§ 161-164). The Act
states, that "[a]ny person ... who has invented or discovered and asexually reproduced any
distinct and new variety of plant. . . may... obtain a patent." Id. sec. 1, § 4886 (current
version at 35 U.S.C. § 161). The Plant Patent Act was passed so that agriculture could reap the
benefits of the patent system as well as industry. See Scalise & Nugent, supra note 75, at 91.
81. Pub. L. No. 91-577, 84 Stat. 1542 (current version at 7 U.S.C. §§ 2321-2582 (1994 &
Supp. 111996)). The Plant Variety Protection Act extended patent protection to some sexually
reproduced plants, provided they satisfy the requirement that they differ in some way from all
prior varieties. See id. sec. 42 (current version at 7 U.S.C. § 2402). This act also gave two
important exemptions from the patent protections. Researchers and farmers were allowed to
reproduce the plants naturally without paying royalties. See Scalise & Nugent, supra note 75,
at 94-95.
82. See Scalise & Nugent, supra note 75, at 95.
83. 447 U.S. 303.
84. See id. at 305.
85. See id. at 306.
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contemplated by the Plant Patent Act or the Plant Variety Protection Act from
patent law, 6 however, Congress failed to accept this invitation.
Although Chakrabarty did not give a full invitation to patent all life forms, the
case certainly opened the door for animal patenting. In 1987, Ex parte Allen
8 7
tested the strength of the Chakrabarty decision for the first time. Ex parte Allen
challenged the rejection of a patent for genetically engineered oysters. The PTO
rejected the patent on the grounds that it was naturally occurring subject matter
and obvious.88 Allen appealed the PTO's rejection to the Board of Patent Appeals
and Interferences, but the board ultimately rejected his application on the
grounds of obviousness. Although Allen's patent application was denied, the
board rejected the claim that the oysters were naturally occurring subject matter
and consequently left open the possibility of patenting a living organism. 9 On
April 7, 1987, immediately following the decision in Ex parte Allen, the PTO
issued a statement reflecting the policy for which Ex parte Allen stood. The PTO
stated:
The Patent and Trademark Office now considers nonnaturally occurring
non-human multicellular living organisms, including animals, to be
patentable subject matter within the scope of 35 U.S.C. 101 [sic].
The Board's decision does not affect the principle and practice that
products found in nature will not be considered to be patentable subject
matter under 35 U.S.C. 101 and/or 102 [sic]. An article of manufacture or
composition of matter occurring in nature will not be considered patentable
unless given a new form, quality, properties or combination not present in the
original article ....
A claim directed to or including within its scope a human being will not
be considered to be patentable subject matter under 35 U.S.C. 101 [sic].9"
This statement made the first animal patent inevitable, and one year later, on
April 12, 1988, the PTO issued a patent for the Harvard Mouse.9'
B. Suitability of Genetic Engineering to Patent Law
By granting patent protection to the Harvard Mouse, the PTO lifted the final
obstacle in the fight for animal patents. However, sensitivity to political
pressures has affected the number of patents and the willingness of the PTO to
86. See id. at 318. The Court stated it was trying to interpret the intention of Congress by
allowing a broad reading of the patent statutes; however, the Court invited Congress to "amend
§ 101 so as to exclude from patent protection organisms produced by genetic engineering." Id.
For a complete discussion of Diamond v. Chakrabarty and its legacy, see Scalise & Nugent,
supra note 75, at 95-101.
87. 2 U.S.P.Q.2d (BNA) 1425 (Bd. Pat. App. & Interferences 1987).,
88. See id. at 1426.
89. See id. at 1427.
90. Patent and Trademark Office Notice: Animals-Patentability, 1077 Official Gazette
U.S. Pat. & Trademark Off. 8 (Apr. 21, 1987).
91. See U.S. Pat. No. 4,736,866 (Apr. 12, 1988).
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actually grant animal patents.92 Although the number of animal patents has
increased, the problem remains that there are still few guidelines and many
unanswered questions. In addition to transgenic animals, scientists wish to patent
human gene sequences and human embryosf 3 It is, therefore, important that there
be a solid foundation in the law of animal patents. A court has yet to decide
whether the PTO exceeded its authority by issuing its statement that they would
grant animal patents.94 Currently, biomedical advances that satisfy the criteria of
novelty, utility, and nonobviousness may receive patent protection.
1. 35 U.S.C. § 102: The Novelty Requirement
Because animals and gene sequences exist naturally, some argue that it is
impossible for such living matter to be novel.95 This argument fails to recognize
the many ways in which biotechnology alters naturally existing organisms so they
differ dramatically from naturally occurring organisms. Additionally, after the
Supreme Court's decision in Chakrabarty,96 it became apparent that normaturally
occurring organisms that have been "man-made" or "man-altered" satisfy the
novelty requirement.97 When a transgenic animal is created, it is a product of
human ingenuity, and it qualifies as patentable under the standard of novelty.98
By issuing its rule contemplating animals as patentable subject matter, the PTO
strengthened the position stated in Chakrabarty.
The case for novelty in human gene sequences is slightly different. Instead of
patenting new animals with genetic material different from that which is found
in nature, scientists seek to patent human gene sequences that certainly occur
naturally. Currently, the policy seems to be to treat human gene sequences like
naturally occurring substances and chemicals.99 Genes may be patented if they
92. See Disclosure Duty and Cost Concerns Dominate "PTO Day" Discussions, BNA Pat.
Trademark & Copyright L. Daily (Jan. 10, 1992), available in WESTLAW, 1/10/92 PTD.
93. Questions abound about the patentability of human embryos because of the age-old
debate about whether an embryo is "human." See Burk, supra note 1, at 1656.
94. See Jones, supra note 34, at 888; see also Animal Legal Defense Fund v. Quigg, 932
F.2d 920 (Fed. Cir. 1991) (failing to reach the actual issue of animal patenting because the
PTO's rule is exempt from the notice-and-comment rule and because those bringing suit did
not have standing to seek the desired declaration).
95. See Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127 (1948) (holding that a
mixed bag of different bacteria, each with a certain function, does not satisfy the novelty
requirement because no new bacteria was created, and each of the bacteria was functioning as
nature originally provided).
96. Diamond v. Chakrabarty, 447 U.S. 303 (1980); see supra Part II.A.
97. Chakrabarty, 447 U.S. at 309.
98. See id.
99. Naturally occurring substances and chemicals may be patented if they are extracted,
isolated, and purified. Additionally, the substances must have some greater value than
previously existed in the natural form. See Matthew Erramouspe, Comment, Staking Patent
Claims on the Human Blueprint: Rewards and Rent-Dissipating Races, 43 UCLA L. REv. 961,
988-90 (1996). See generally Merck & Co. v. Olin Mathieson Chem. Corp., 253 F.2d 156 (4th
Cir. 1958) (upholding a patent for a vitamin B concentrate which had been extracted from its
natural form and purified); Parke-Davis & Co. v. H.K. Mulford & Co., 196 F. 496 (2d Cir.
1912) (upholding a patent for adrenaline isolated from animal suprarenal glands).
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are in an isolated and purified form, but not if they are simply in the form in
which the scientist discovered the sequence."0 Gene sequences contain a great
deal of extraneous information because they are comprised of sections which
code for proteins as well as sections that do not. When scientists clone
sequences, they isolate only the protein-coding portions, thus isolating and
purifying the gene sequence.'0" Applying these standards of novelty, it is
appropriate that isolated and purified gene sequences be awarded patent
protection in accordance with the novelty standard.
2. 35 U.S.C. § 101: The Utility Requirement
Transgenic animals and human gene sequences are clearly. useful. As
previously discussed, biotechnology utilizes transgenic animals and human gene
sequences to develop disease models, pharmaceuticals, and improved food
products.0 2 Some claim, however, that the standard of utility has been elevated
for biotechnological innovations. In most technologies, the utility standard is
considered de minimis. However, because many of the innovations in
biotechnology seem "unbelievable," patents have sometimes been refused for
lack of utility. 3 Fortunately, guidelines that do not require human clinical trials
to be performed before an innovation is accepted as useful have squelched this
trend somewhat. The guidelines, additionally, now require the PTO examiner to
clearly assert why an innovation is rejected for lack of utility.'
Because scientists generally create transgenic animals with a specific use in
mind, the utility requirement does not pose a significant roadblock to patent
protection. Gene sequences are more difficult, however, because once sequences
are discovered and purified, it is often known that they produce human protein,
but not what the actual function of the protein is.0 5 In these cases, the patent
applicants try to show that the gene sequences function as different types of
markers, probes, and primers for various genetic research."° If the applicants are
capable of showing that their sequence can be utilized for one of these purposes,
they will have satisfied the utility requirement under 35 U.S.C § 101.107
100. See Erramouspe, supra note 99, at 988.
l01.See id. at 991.
102. See supra Part I.C.
103. See Seide & Smith, supra note 21, at 55.
104. See PTO Examination Guidelines on Utility Requirement, 50 Pat. Trademark &
Copyright J. (BNA) 295, 304-05 (July 20, 1995); see also In re Brana, 51 F.3d 1560 (Fed. Cir.
1995) (holding human testing of pharmaceuticals not necessary to satisfy the utility
requirement).
105. See Christopher A. Michaels, Biotechnology and the Requirement for Utility in Patent
Law, 76 J. PAT. [& TRADEMARK] OFF. Soc'y 247, 258 (1994).
106. These three uses involve segments of cloned DNA. Markers are used to identify
individual human chromosomes, probes are used in genetic screening, and primers are used for
genetic fingerprinting. See id. at 259.
107. See id.
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3. 35 U.S.C. § 103: The Nonobviousness Requirement
A 1995 amendment to 35 U.S.C. § 103 somewhat revamped the
nonobviousness requirement in order to incorporate biotechnology.' 2 The basic
tenets have remained the same, however. In order to ascertain the obviousness
of an invention, the invention must be viewed in light of other inventions in the
prior art. If the new invention is one which could be easily accomplished by one
with skill in the prior art, the invention will not be granted a patent.'0 9
Obviousness has been a sticky subject in the realm of biotechnology because
scientists use similar techniques to isolate different gene sequences, even though
the gene sequence may be new."0
The Federal Circuit decision of In re Deuel"' dealt directly with the
obviousness requirement for biotechnology. The court seemed to relax the
obviousness standard by stating that "[a] general motivation to search for some
gene that exists does not necessarily make obvious a specifically-defined gene
108. See 35 U.S.C.A. § 103(b) (West Supp. 1997).
(1) Notwithstanding subsection (a), and upon timely election by the applicant for
patent to proceed under this subsection, a biotechnological process using or
resulting in a composition of matter that is novel under section 102 and
nonobvious under subsection (a) of this section shall be considered nonobvious
if-
(A) claims to the process and the composition of matter are contained in either the
same application for patent or in separate applications having the same effective
filing date; and
(B) the composition of matter, and the process at the time it was invented, were
owned by the same person or subject to an obligation of assignment to the same
person.
(2) A patent issued on a process under paragraph (1)-
(A) shall also contain the claims to the composition of matter used in or made by
that process, or
(3) shall, if such composition of matter is claimed in another patent, be set to
expire on the same date as such other patent, notwithstanding section 154.
(3) For purposes of paragraph (1), the term "biotechnological process" means-
(A) a process of genetically altering or otherwise inducing a single- or multi-
celled organism to-
(i) express an exogenous nucleotide sequence,
(ii) inhibit, eliminate, augment, or alter expression of an endogenous nucleotide
sequence, or
(iii) express a specific physiological characteristic not naturally associated with
said organism;
(B) cell fusion procedures yielding a cell line that expresses a specific protein,
such as a monoclonal antibody; and
(C) a method of using a product produced by a process defined by subparagraph
(A) or (B), or a combination of subparagraphs (A) and (B).
Id.
109. See Graham v. John Deere Co., 383 U.S. 1 (1966).
110. See Rebecca S. Eisenberg, Patenting the Human Genome, 39 EMORY L.J. 721, 736
(1990).
111.51 F.3d 1552 (Fed. Cir. 1995).
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that is subsequently obtained as a result of that search. More is needed and it is
not found here."".2 This decision allowed patents to be granted for DNA
molecules even if the method for finding the DNA was obvious". and seemed
inconsistent with previous understanding of the nonobviousness requirement." 4
The 1995 amendment to 35 U.S.C. § 103, however, seems to require that both the
process and the molecule be nonobvious to satisfy the nonobviousness
requirement.
Clearly, many biotechnology advances are capable of satisfying the
requirements for patentability. From a purely legal standpoint, innovations in
biotechnology are as capable as those in any other field of being useful, novel,
and nonobvious. Patents are legally appropriate. The crux of the patent debate,
however, has never really been the ability of biotechnology to satisfy the
requirements. The debate has centered primarily on whether we should reject
patents for biotechnology for social reasons, regardless of their novelty, utility,
and nonobviousness.
III. SOCIAL CONSIDERATIONS: DISCIPLINARY CONCERNS IN
PATENTING BIOTECHNOLOGY
Legally, many transgenic animals and gene sequences satisfy the standards for
patent protection. The more difficult question is whether patent applications for
transgenic animals and gene sequences should be denied for moral and ethical
reasons. "5 Many, however, argue that morality is not one of the criteria on which
the PTO issues patent protection. " 6 It is undisputed that biotechnology is capable
of remarkable benefits to society. The advances in biotechnology and the PTO's
willingness to grant patent protection to the creators of transgenic animals,
however, have spurred fear and controversy in economic, environmental, and
ethical spheres of thought." 7 The President himself, in fact, has stated that
"[t]he breathtaking advances in science and technology demand that we always
112. Id. at 1558. The court justified its decision by basing it on the decision in In re
O'Farrell, 853 F.2d 894 (Fed. Cir. 1988), which held "obvious to try" did not make an
invention "obvious." If an invention was "obvious to try" but satisfied three other criteria, it
would satisfy the nonobviousness requirement. The three indicia are: 1) there must be no
expectation of success, 2) there must be no indication in the prior art disclosing what was
necessary to vary in order to reach the desired result, and 3) there must be only general
guidance in the prior art. See Eisenberg, supra note 110, at 732.
113. See Seide & Smith, supra note 21, at 57.
114. See Philippe Ducor, The Federal Circuit and In re Deuel: Does § 103 Apply to
Naturally Occurring DNA?, 77 J. PAT. [& TRADEMARK] OFF. SOc'y 871, 898 (1995).
115. See Barbara Looney, Note, Should Genes Be Patented? The Gene Patenting
Controversy: Legal, Ethical and Policy Foundations of an International Agreement, 26 LAW
& POL'Y INT'L Bus. 231, 271-72 (1994).
116. See James R. Chiapetta, Comment Of Mice and Machine: A Paradigmatic Challenge
to Interpretation of the Patent Statute, 20 WM. MITCHELL L. REV. 155, 178 (1994).
117. See Sellers, supra note 12, at 283.
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keep our ethical watch light burning.""'" Others state, however, that although the
arguments advanced by biotechnology-patenting opponents seem emotionally and
politically compelling, they rest on a poor logical framework." 9 Patenting
proponents state that morality and ethics are not properly debated in the area of
patent law, but rather these are issues that Congress should address while
discussing appropriate regulations for biotechnology research as a whole. 2 '
A. Agricultural Concerns
Although transgenic animals have much to offer to the productivity and quality
of farm animals,' small family farmers fear allowing patents on transgenic
animals will push them out of the market. The same increased productivity that
sounds so economically desirable sounds like financial ruin to small family
farms. Because genetically created animals will likely be expensive, small
farmers fear that a small number of large corporations will be able to corner the
market on genetically engineered animals, thereby depriving the small family
farms of their livelihood.' Additionally, the farmers are concerned that the
initial acquisition price of genetically altered animals, and the subsequent
royalties, will increase rather than decrease the costs for farmers and
consumers.
23
This position is fairly weak, however, because the transgenic farm animals will
be stronger and more disease resistant, and should balance the cost of the initial
investment. 24 Proponents of animal patents additionally point out that the patent
protection for the transgenic animals may actually help the farmers. This
argument suggests that without PTO-issued protection, the owners of the
transgenic animals will license their animals selectively, resulting in a small
concentration of significantly advantaged, commercialized farming.'25 The
position of the small farmers weakens further when it is considered that the main
interest in transgenic animals is currently in medical research. Transgenic farm
animals are certainly possible; however, the inception of large numbers of such
animals in the near future is considered unlikely.
26
Finally, not all farmers object to the idea of patented farm animals. The
American Farm Bureau Federation ("AFBF"), which consists of 3.7 million
118. Ruth Faden, The Advisory Committee on Human Radiation Experiments: Reflections
on a Presidential Commission, HASTINGS CTR. REP., Sept.-Oct. 1996, at 5, 9 (alteration added)
(quoting President Clinton).
119. See Burk, supra note 1, at 1639.
120. See Jones, supra note 34, at 915.
121. See supra Part I.C.3.
12. See Rebecca Dresser, Ethical and Legal Issues in Patenting New Animal Life, 28
JuaiMErcs J. 399, 417 (1988).
123. See Sellers, supra note 12, at 285.
124. See Jozwiak, supra note 54, at 628.
125. See Sellers, supra note 12, at 286.
126. See id. at 285.
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member families, strongly supports the patenting of transgenic farm animals.' 27
In fact, the AFBF did not support the Transgenic Animal Patent Reform Act of
1989 because it allowed too much of a farmers' exemption, and would have
allowed unfair competition between the patent holders and those farmers allowed
to reproduce the farm animals without paying royalties. 2 '
Although the Transgenic Animal Patent Reform Act did not pass the Senate,' 29
this sort of legislation is the appropriate response to the concerns of small
farmers. The PTO is not the appropriate body to weigh the effects of patented
subject matter on particular markets. The PTO's job is to decide novelty, utility,
and nonobviousness. Carefully drafted legislation, with additions to those
suggested by the AFBF, 3 ' will better serve the concerns of small family farmers
while allowing biomedical advances to continue to progress.
B. Environmental Concerns
Some environmental groups are concerned with the fact that we do not have
clear ideas of what could happen if these transgenic organisms were set free in
the environment. The National Wildlife Foundation ("NWF") opposes patenting
for transgenic animals because of the lack of legislation in the area concerning
their release into the wild.' Although rejecting patent applications for
transgenic animals does not mean the creation and release of such animals is
prohibited, the NWF fears that allowing patents will cause a greater number of
transgenic animals to be created, thus increasing the risk to the environment.'
13 2
There is really nothing known about the long-term effects of releasing
transgenic animals into the environment. However, some environmentalists
speculate that such a release might be real and possibly harmful to human and
environmental health.'33 This argument fails to acknowledge, however, that the
127. See Transgenic Animal Patent Reform Act of 1989: Hearings on H.R. 1556 Before the
Subcomm. on Courts, Intellectual Property, and the Admin. of Justice of the House Comm. on
the Judiciary, 101st Cong. 33 (1989) [hereinafter Patent Reform Act Hearings] (statement of
Donald Haldeman, President, Wisconsin Farm Bureau Federation, on behalf of the AFBF).
128. See id. at 35. The proposed farmers' exemption would have allowed any occupational
farmer to reproduce transgenic animals through breeding for any purposes. See id. at 36. The
AFBF feared this exemption would reduce the incentive to develop transgenic animals in the
future. The AFBF suggested language that would better restrict the uses of those animals
reproduced through breeding to farming uses and sale for nonreproductive uses. See id. at 35-
36.
129. See Moga, supra note 12, at 519.
130. See supra note 128.
13 1. See Patent Reform Act Hearings, supra note 127, at 226-27 (statement of Margaret
Mellon, Director, National Biotechnology Center, NWF).
132. See id.
133. See The Evaluation of Federal Programs in Agricultural Research, Educ., and
Extension: Hearings Before the Subcomm. on Resource Conservation, Research, and Forestry
of the House Comm. on Agric., 104th Cong. 250 (1996) (statement of Margaret Mellon, Union
of Concerned Scientists). Some of the arguments postulated by environmentalists claim that
transgenic animals in the wild will cause a loss of species integrity. This argument, however,
makes the incorrect assumption that all species are completely distinct. Rather, transgenic
animals may be better for species integrity than traditional selective breeding because scientists
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release of "naturally" occurring organisms into new environments is also
detrimental to environmental health.3 Although the uncertain nature of the
environmental effects is certainly a plausible argument for regulating the release
of transgenic animals into the wild, the argument has little to do with patenting,
and should not be a substantial roadblock to the patenting of transgenic animals.
The availability of patents for biotechnology should not be used as an
environmental-regulation mechanism. Nuclear weapons are the only example of
inventions that have been denied patent protection for the safety of the public.'
The only possible function of the atomic bomb is to kill. Biotechnology is
capable of so many public benefits that it should not be stifled by denying it
patent protection. The concerns of the NWF and other environmentalists are
valid, however, which is why the EPA should review the appropriateness of
biotechnology practice. If necessary, regulations regarding the creation and
release of transgenic animals could be easily created. Requiring the PTO to
decide the possible environmental consequences of furthering biotechnology
research again takes the PTO out of its role of deciding novelty, utility, and
nonobviousness.
C. Animal-Rights Concerns
Concerns about the cruel treatment of animals are quite prevalent in
discussions about transgenic animals. It is true that many of the animals
engineered to help in human-disease research are bred to suffer from such
diseases as AIDS, sickle cell anemia, cystic fibrosis, and cancer."3 6 Although it
is unpleasant to consider the experimental conditions that these transgenic
research animals must endure, denying patent protection will not ease their
suffering. Animals have been research subjects for a very long time, and humans
have benefitted immeasurably from their use.'
It is quite possible that transgenic animals will actually limit the amount of
animal suffering endured by research subjects and animals in general. For
instance, using transgenic animals requires the use of fewer animals because the
animals are created for the particular study purpose and are more responsive to
the experimentation. 38 Similarly, fewer research animals (such as mice) are
needed for each experiment because they have been engineered to be healthier,
and are less likely to die of causes other than the research. 39 Additionally, the
whole point of transgenics in agriculture is not to create freakish chimeras but
can retain overall genetic diversity, only singling out a desirable genetic trait. See Chiapetta,
supra note 116, at 179.
134. For example, gypsy moths were intentionally introduced into this country and now they
are responsible for the destruction of acres of forest. See Sellers, supra note 12, at 290.
135. See Robert S. Wasowski, The Evolution of Patentable Compositions of Matter: The
United States Patent Office Accepts Genetically Altered Animals as Patentable Subject Matter
Under 35 U.S.C. § 101, 2 ADMIN. L.J. 309, 327 (1988).
136. See Cone, supra note 38, at Al.
137. See Jozwiak, supra note 54, at 628.
138. See id.
139. See Genetically Engineered Mouse, supra note 47, at 2G.
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rather to create healthier animals. 4 ' Patenting these transgenic animals may limit
the necessary amount of animal suffering. Because patents serve as economic
incentives, transgenic animals that do not improve market value will not be
economically desirable and will not be produced. 4 '
It is indisputable that some animals suffer with transgenic research; however,
animals may suffer even more with traditional animal research. It seems that it
is not the patenting of the transgenic animals that is bothersome to animal-rights
activists, but rather the actual science and the transgenic research.' 42 Denying
patents for transgenic animals will not stop transgenic-animal research. Those
truly concerned with animal rights in transgenic research should be asking
Congress to regulate the types of research performed, and not the patent
protection extended.'43 Legislation already exists that limits animal research, and
transgenic research is not among the varieties limited.14 Opponents to transgenic
animal research may be better served by lobbying to have this legislation
expanded rather than opposing the patentability of all transgenic animals and
stifling biotechnological advance. If the treatment of animals has no bearing on
the novelty, utility, or nonobviousness of an invention, the PTO is not in a
position to make its decision based on the treatment of animals.
D. Moral and Religious Concerns
Similar to the debate about animal rights, those opposed to patenting
biotechnology based on moral or religious concerns seem to be much more
opposed to the existence of the science, rather than the existence of patents for
the discoveries. The general concern is that research in biotechnology is "playing
God" and undermining the "sanctity of life" as God created it. 45 This position
loses sight of the fact that biotechnological research is performed to help the
human condition rather than harm it. These arguments, however compelling, are
not aimed at the patent process, but rather at the research itself. 46
It is usually not the issuance of patents that evokes the moral dilemma, but
rather misconceptions about biotechnology. 47 However, sonie feel that the
sanctity of life is not well served by allowing the creation of transgenic animals.
The argument then suggests that patenting animal life exacerbates the problem.
One commentator suggested that the PTO turned animals into commercial
140. For example, a chicken has been engineered to resist a common ailment: the avian
leukemia virus. See Chiapetta, supra note 116, at 183.
141. See id.
142. See Mark, supra note 12, at 253-54.
143. See Landau, supra note 4, at 221.
144. See Mark, supra note 12, at 254.
145. See id. at 257; see also Purnell, supra note 69, at 1193 (noting the risks involved in the
creation or alteration of new and existing life forms).
146. See Jozwiak, supra note 54, at 629.
147. See Burk, supra note 1, at 1643; see also Chiapetta, supra note 116, at 189 (suggesting
that the arguments against animal patents are more compelling when made against the
technology which the patents protect).
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commodities, and likened them to "electric toasters and automobiles."'48 If the
role of the PTO is to act as a regulator of the societal impact of technologies,
then it is possible that it should make these considerations when deciding
whether to grant a patent to an applicant. The role of the PTO should not be to
act as a regulator of societal impact, however, and the requirements for
successfully obtaining a patent should remain solely in novelty, utility, and
nonobviousness.
IV. RESOLUTIONS: LIMITS, LAWS, AND THE ULTIMATE
BENEFIT OF BIOTECHNOLOGY PATENTING
Until 1995, the U.S. carried the dubious distinction of being one of the few
industrialized nations without a commission to examine bioethics.'49 Finally, the
NBAC was formed on October 3, 1995.150 In forming this Commission, President
Clinton has required that one high priority is to review the appropriateness and
implications of human gene patenting.' Although President Clinton instructed
the Commission to address human gene patenting as one of its first issues, 152 to
date no discussion has commenced. This leaves us to grapple with the still
uncertain state of "animal patent law" to determine the appropriateness of
granting patents for human gene sequences.
A. Suggested Limits
Transgenic animals and human gene sequences, as well as other biotechnology,
may be patented under our current system of patent law. The parameters for these
patents remain unknown, however, because no clear dialogue and resolution have
taken place in Congress. 5 3 It is inappropriate for the PTO to make far-reaching
ethical decisions simply by granting or rejecting a patent application based on
existing statutes. However, it is also inappropriate for the PTO to step outside of
its role of deciding patents based on novelty, utility, and nonobviousness."'
Many concerns possessed by biotechnology-patenting opponents are more
appropriately addressed by agencies and legislation separate from the PTO
because the problem lies not with biotechnology patenting, but with
biotechnology.'55 There are some concerns, however, aimed directly at
148. Jones, supra note 34, at 886.
149. See Hatfield, supra note 5, at 7.
150. See Exec. Order 12,975, 3 C.F.R. 409 (1996); supra text accompanying note 8.
151. See Exec. Order 12,975, 3 C.F.R. 409; see also Morning Edition: New Federal
Bioethics Commission Convenes Today (NPR radio broadcast, Oct. 4, 1996) (transcript
available in 1996 WL 12730100) (noting that President Clinton created the NBAC to first
consider the safeguards of human experimentation and genetic patenting).
152. See Exec. Order 12,975, § 1, 3 C.F.R. at 409-10.
153. See Lorance L. Greenlee, Biotechnology Patent Law: Perspective of the First Seventeen
Years, Prospective on the Next Seventeen Years, 68 DENV. U. L. REV. 127, 137 (1991); see also
Hatfield, supra note 5, at 6 (noting that consideration of genetic alteration has not taken place).
154. See Hatfield, supra note 5, at 6.
155. See supra Part III (discussing the concerns of biotechnology).
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biotechnology patenting, and in the absence of congressional guidance, the PTO
may make its decisions based on novelty, utility, and nonobviousness, and
perhaps issue patents for subject matter Congress would prefer it did not for
social or ethical reasons. A safeguard in addition to agency regulation and
legislation is therefore necessary.
Creation of the NBAC is an important first step in evaluating the consequences
and importance of patents on biotechnology. The NBAC should evaluate the
different possible approaches for Congress to take concerning biotechnology
patents and consider the long-term consequences of each. It is far more
appropriate for the NBAC to make these moral, ethical, and societal decisions
regarding the long-term effect of biotechnology patents than for the PTO to make
them. It is important for the NBAC to acknowledge a position on animal
patenting as well as human gene patenting so the debate may finally come to rest
on solid principles, rather than "allow such issues to be decided by default in a
vacuum of leadership."'
156
Suggestions for the limitations of biotechnology and biotechnology patents
range from fines and jail time for misuse of the technology to accepting the status
quo.'57 One commentator has suggested that the PTO weigh the costs and benefits
of each biotechnology patent application in addition to the three current patent
criteria. If too many negative social implications could possibly arise from the
issuance of the patent, it would be denied. 5 This would essentially add a fourth
criterion to the patent laws for biotechnology: social implication. Perhaps this is
the ideal rule from a social standpoint; however, the practical implementation of
such a rule would be nearly impossible, and the PTO is not the appropriate body
to make such decisions.
A more practical approach would be for the NBAC to identify and separate
categories of biotechnology research (rather than individual applications) that are
appropriate (from a social standpoint) for patents from those that are not. Such
categories could include transgenic research animals, transgenic farm animals,
transgenic animals for the production of pharmaceuticals, isolated human gene
sequences with known utility, and human gene sequences with unknown utility.
Isolating separate categories of biotechnology will allow more independent
evaluation of the social implications at stake and thoughtful decisions regarding
the patentability of more narrow categories than limiting the discussion to the
issue of biotechnology patenting as a whole. A categorical approach will prove
far more workable than individual evaluation of the long-term implications of
granting each biotechnology patent application. The NBAC should then present
these categories to Congress for adoption under Title 35. Creating categories and
offering suggestions as to the appropriateness of patent protection for each
156. Haffield, supra note 5, at 5.
157. See Jones, supra note 34, at 904-05; see also Richard Kevin Zepfel, Note, Stopping a
"Gruesome Parade of Horribles": Criminal Sanctions to Deter Corporate Misuse of
Recombinant DNA Technology, 59 S. CAL. L. REV. 641, 658 (1986) (noting that some
commentators have suggested collecting fines from the "white-collar criminal" genetic-
engineering corporations).
158. See generally Paul B. Thompson, Conceptions of Property and the Biotechnology
Debate, 45 BIOSCIENCE 275 (1995).
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category would give the PTO some guidance so that the PTO may continue to
decide "novelty" rather than "morality."'59 There is some guidance existing in the
Constitution, current precedent, and formerly proposed legislation to aid in the
creation of such guidelines.
B. Helpful Guidance for a Clear Standard
The issues of patenting humans, the breadth of biotechnology patents, and
infringement exemptions for certain classes of people are all valid concerns
dealing directly with biotechnology patent law, and these are concerns that must
all be addressed in order to give guidance to the PTO. The issue that generally
garners the most hysterical reactions when discussing biotechnology and
patenting is the possibility of patenting a "human" or an animal such as a
chimpanzee that has been engineered to be "partially human" in order to perform
menial human tasks. 6 ° Although the likelihood of such an invention is slim, and
although most of the concern stems from the existence of such a creature rather
than its patentability, under current patent laws such a creature might be able to
satisfy the criteria for a patent. The PTO maintains its position that it will not
issue a patent for a human;' 6 1 however, scientists currently combine human gene
sequences with mice to create transgenic animals that have been patented. This
raises a fundamental question: How much human genetic material must be
inserted into another organism to make it human enough to prohibit patenting?
The NBAC must address this question in order to create workable guidelines.
Some argue that the Thirteenth Amendment restricts patenting transgenic
humans. 62 This argument is faulty because the Thirteenth Amendment does not
prohibit patenting of transgenic animals with some human genetic component;
rather, it prohibits the use of a human for servitude. 63 Taking cues from the
Thirteenth Amendment, however, the PTO may easily institute a policy to reject
patent applications for anything remotely resembling a transgenic human.
Contemplating transgenic humans is probably the most extreme issue the NBAC
and PTO would have to address. More imminent issues involve the breadth of
animal patents and the economic concerns of farmers and researchers who would
be using, and necessarily reproducing, transgenic animals.
The initial patent granted for the Harvard Mouse was quite broad. Under the
Harvard Mouse patent, the creation of any animal with a susceptibility to cancer
due to the prescribed method could possibly infringe upon the patent.'" Since the
PTO issued the Harvard Mouse patent, subsequent successful animal patents
159. See Science Blooming, supra note 8.
160. See Dresser, supra note 122, at 407.
161. See supra note 8 and accompanying text.
162. "Neither slavery nor involuntary servitude, except as a punishment for crime whereof
the party shall have been duly convicted, shall exist within the United States, or any place
subject to their jurisdiction." U.S. CONST. amend. XIII, § 1.
163. See Burk, supra note 1, at 1647-48.
164. See Landau, supra note 4, at 215.
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have been far more limited in scope.'65 This trend should continue to be followed
in order to encourage more participation in biotechnology. By allowing specific,
limited-scope patents, no one process or technique will overtake the industry, and
research will not be stifled.
Finally, as discussed previously, Congress should seriously consider the
possibility of limited farmers' and researchers' exemptions from patent
infringement. A farmers' exemption was proposed in the Transgenic Animal
Patent Reform Act of 1989.166 The proposed legislation would have allowed
farmers to breed transgenic animals without having to pay royalties for their
offspring. This proposal was passed in the House of Representatives, but failed
in the Senate.'67 Some objectors to the proposed legislation felt the exemptions
were too broad and should have been limited only to those farmers who used the
animals for sale in nonreproductive roles. Though the Transgenic Animal Patent
Reform Act failed, a more narrowly drafted form of this legislation is a good
means of remedying the concerns of small family farmers. The NBAC should
weigh the merits of such an exemption, and consider the benefits of a similar
exemption for those using transgenic animals for research purposes. 61
C. The Benefits Prevail
Denying patents for biotechnology will result in the inhibition of competitively
priced goods and a reduced initial incentive to engage in biotechnological
studies. 169 Patent protection gives companies reasons to expand their research in
genetics, and ensures that such research will continue. 7 ° Allowing patents on
biotechnology will encourage investment in studies valuable in the quest to
combat disease and improve the quality of food. 7' Such an incentive is necessary
because biotechnology is a high-risk, high-cost form of research. Patent
protection will create the kinds of economic incentives necessary for people to
engage in this research and, ultimately, drastically improve public health.'72
Harm from the misuse of technology should not be grounds for denial of patent
protection, but it should be a good reason for better regulation of the trade and
patent practice used in biotechnology.' Issuing patents may actually allow better
visibility of biotechnology because patents will encourage disclosure of
165. See Moga, supra note 12, at 520-21. Other animals which have received patents include
both rabbit and mouse models for AIDS testing. These patents are limited to the specific
animals and the specific methods, thus limiting significantly the scope of the patents. See id.
166. See Patent Reform Act Hearings, supra note 127.
167. See Moga, supra note 12, at 519.
168. See Eisenberg, supra note 110, at 743. "An experimental use exemption from
infringement liability could prevent patents from burdening the progress of research science
while still preserving incentives for private investment in research and development in
biotechnology." Id.
169. See Chiapetta, supra note 116, at 160, 176.
170. See Scalise & Nugent, supra note 75, at 97.
171. See Jozwiak, supra note 54, at 624.
172. See Beier & Benson, supra note 70, at 190.
173. See Chiapetta, supra note 116, at 182.
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advances. 74 If secrecy becomes unnecessary, then protection of the public good
will be enhanced by keeping tabs on what is going on in this world 75 of
"uncertain science and explosive growth."'76
Clearly aspects of biotechnology are present that require careful consideration
before issuing patents. Although, on their faces, biotechnology inventions may
satisfy the existing patent laws, moral, ethical, and social implications also exist
which require thoughtful consideration. In the end, however, the benefits of
issuing patents for biotechnology will outweigh the costs.
CONCLUSION
The economic and social benefits of patenting transgenic animals and gene
sequences far outweigh the possible social costs. Biotechnology holds the key to
finding cures for many of our most serious and baffling diseases, improving the
quality of our food, and making our pharmaceuticals more cost-effective to
produce. Most of the concern with biotechnology patents is not directed at patent
law, but rather at the technology itself. The PTO is, therefore, not the appropriate
agency to make decisions about the appropriateness of biotechnology research.
Additionally, denial of patent protection is not an appropriate or effective means
of conduct control. Instead, agencies with expertise in the areas of concern177 and
legislation specifically tailored to deal with the areas of concern7 should be
employed to ameliorate these problems.
Moreover, denying animal patents will not defeat biotechnology research, it
will just suppress it. Because biotechnology is a discipline which will serve to
improve the human condition, the answer should be to allow biotechnology to
flourish through the granting of patents. 79 As an additional safeguard to agency
evaluation and legislation, guidelines for biotechnology patents should be formed
with social implications in mind.
Congress, with the guidance of the NBAC, should certainly evaluate the social
and moral concerns of biotechnological patenting. A careful review of the
potential problems will reveal that the majority of biotechnology advance is
appropriate under the current patent laws, and in terms of the societal benefit
such advance will create. By creating standards that address the fears of patent
opposers, however, those who have "the genius to make a significant
174. See Jozwiak, supra note 54, at 624.
175. See Moga, supra note 12, at 518.
176. Revitalizing New Product Development, supra note 2, at 106 (statement of David A.
Kessler, Commissioner, Food and Drug Administration, Department of Health and Human
Services).
177. For example, the EPA may deal with the concerns of environmentalists to create
guidelines to deal specifically with the release of transgenic animals into the wild. See supra
Part III.B.
178. For example, legislation similar to the Transgenic Animal Patent Reform Act. See supra
Part III.A.
179. See, e.g., Chiapetta, supra note 116, at 181 (noting the societal need for the regulation,
not suppression, of biotechnology patenting).
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[biotechnological] advance" will be able to reap the benefits of patent protection
that they deserve."'0
180. Beier & Benson, supra note 70, at 183.
